Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
Abstract
:1. Introduction
2. Results
2.1. PD-L1 Expression Status between Part-Solid and Pure-Solid Tumors
2.2. Multivariate Analysis Using Clinical Factors
2.3. Histological Features and PD-L1 Expression Status
2.4. Prognostic Impact of PD-L1 Expression
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Staining
4.3. Statistical Analysis
Author Contributions
Funding
Conflicts of Interest
References
- Travis, W.D.; Bankier, A.A.; Beasley, M.B.; Flieder, D.B.; Goo, J.M.; MacMahon, H.; Naidich, D.; Powell, C.A.; Prokop, M.; Yatabe, Y.; et al. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J. Thorac. Oncol. 2016, 11, 1204–1223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aokage, K.; Miyoshi, T.; Ishii, G.; Kusumoto, M.; Nomura, S.; Katsumata, S.; Sekihara, K.; Hishida, T.; Tsuboi, M. Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification. J. Thorac. Oncol. 2017, 12, 1403–1412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aokage, K.; Miyoshi, T.; Ishii, G.; Kusumoto, M.; Nomura, S.; Katsumata, S.; Sekihara, K.; Tane, K.; Tsuboi, M. Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer. J. Thorac. Oncol. 2018, 13, 533–542. [Google Scholar] [CrossRef] [PubMed]
- Hattori, A.; Hirayama, S.; Matsunaga, T.; Hayashi, T.; Takamochi, K.; Oh, S.; Suzuki, K. Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma. J. Thorac. Oncol. 2019, 14, 265–275. [Google Scholar] [CrossRef] [PubMed]
- Hattori, A.; Matsunaga, T.; Takamochi, K.; Oh, S.; Suzuki, K. Importance of Ground Glass Opacity Component in Clinical Stage IA Radiologic Invasive Lung Cancer. Ann. Thorac. Surg. 2017, 104, 313–320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berry, M.F.; Gao, R.; Kunder, C.A.; Backhus, L.; Khuong, A.; Kadoch, M.; Leung, A.; Shrager, J. Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival. Clin. Lung Cancer 2017, 19, e47–e51. [Google Scholar] [CrossRef] [PubMed]
- Kinoshita, F.; Toyokawa, G.; Matsubara, T.; Kozuma, Y.; Haratake, N.; Takamori, S.; Akamine, T.; Hirai, F.; Takenaka, T.; Tagawa, T.; et al. Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. Anticancer Res. 2019, 39, 2665–2670. [Google Scholar] [CrossRef] [PubMed]
- Miyoshi, T.; Aokage, K.; Katsumata, S.; Tane, K.; Ishii, G.; Tsuboi, M. Ground-glass opacity is a strong prognosticator for pathologic stage IA lung adenocarcinoma. Ann. Thorac. Surg. 2019, 108, 249–255. [Google Scholar] [CrossRef] [PubMed]
- Toyokawa, G.; Takada, K.; Okamoto, T.; Shimokawa, M.; Kozuma, Y.; Matsubara, T.; Haratake, N.; Takamori, S.; Akamine, T.; Katsura, M.; et al. Computed Tomography Features of Lung Adenocarcinomas with Programmed Death Ligand 1 Expression. Clin. Lung Cancer 2017, 18, e375–e383. [Google Scholar] [CrossRef] [PubMed]
- Hirsch, F.R.; McElhinny, A.; Stanforth, D.; Ranger-Moore, J.; Jansson, M.; Kulangara, K.; Richardson, W.; Towne, P.; Hanks, D.; Vennapusa, B.; et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J. Thorac. Oncol. 2017, 12, 208–222. [Google Scholar] [CrossRef] [PubMed]
- Rimm, D.L.; Han, G.; Taube, J.M.; Yi, E.S.; Bridge, J.A.; Flieder, D.B.; Homer, R.; West, W.W.; Wu, H.; Roden, A.C.; et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017, 3, 1051–1058. [Google Scholar] [CrossRef] [PubMed]
- Herbst, R.S.; Baas, P.; Kim, D.-W.; Felip, E.; Perez-Gracia, J.L.; Han, J.-Y.; Molina, J.; Kim, J.-H.; Arvis, C.D.; Ahn, M.-J.; et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016, 387, 1540–1550. [Google Scholar] [CrossRef]
- Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef] [PubMed]
- Shimoji, M.; Shimizu, S.; Sato, K.; Suda, K.; Kobayashi, Y.; Tomizawa, K.; Takemoto, T.; Mitsudomi, T. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 2016, 98, 69–75. [Google Scholar] [CrossRef] [PubMed]
- Hirsch, F.R.; Suda, K.; Wiens, J.; Bunn, P.A. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016, 388, 1012–1024. [Google Scholar] [CrossRef]
- Osarogiagbon, R.U.; Veronesi, G.; Fang, W.; Ekman, S.; Suda, K.; Aerts, J.G.; Donington, J. Early-Stage NSCLC: Advances in Thoracic Oncology 2018. J. Thorac. Oncol. 2019, 14, 968–978. [Google Scholar] [CrossRef] [PubMed]
- Forde, P.M.; Chaft, J.E.; Smith, K.N.; Anagnostou, V.; Cottrell, T.R.; Hellmann, M.D.; Zahurak, M.; Yang, S.C.; Jones, D.R.; Broderick, S.; et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N. Engl. J. Med. 2018, 378, 1976–1986. [Google Scholar] [CrossRef] [PubMed]
Factors | Part-Solid LAD (n = 45) | Pure-Solid LAD (n = 79) | p-Value |
---|---|---|---|
Age | |||
≤68 year/≥69 year | 20 (44%)/25 (56%) | 44 (56%)/35 (44%) | 0.23 |
Sex | |||
Male/Female | 20 (44%)/25 (56%) | 37 (47%)/42 (53%) | 0.80 |
Smoking status * | |||
Smokers/Never smokers | 13 (33%)/27 (67%) | 30 (47%)/34 (53%) | 0.15 |
PD-L1 Expression | |||
≥1%/<1% | 2 (4%)/43 (96%) | 20 (25%)/59 (75%) | <0.01 |
PD-L1 strong expression | |||
≥50%/<50% | 1 (2%)/44 (98%) | 13 (16%)/66 (84%) | 0.02 |
Factors | Univariate Analysis | p-Value | Multivariate Analysis | p-Value | ||
---|---|---|---|---|---|---|
Odds Ratio | 95% CI | Odds Ratio | 95% CI | |||
Age | ||||||
≤68 year vs. ≥69 year | 8.0 | (2.2–28.6) | <0.01 | 7.0 | (1.7–28.6) | <0.01 |
Sex | ||||||
Male vs. Female | 1.5 | (0.6–3.8) | 0.38 | - | - | - |
Smoking status | ||||||
Smoker vs. never smoker | 4.3 | (1.4–13.5) | 0.01 | 4.0 | (1.2–13.9) | 0.03 |
CT findings | ||||||
Pure-solid LAD * vs. part-solid LAD | 7.3 | (1.6–32.9) | <0.01 | 5.9 | (1.2–29.7) | 0.03 |
Factors | Univariate Analysis | p-Value | Multivariate Analysis | p-Value | ||
---|---|---|---|---|---|---|
Odds Ratio | 95% CI | Odds Ratio | 95% CI | |||
Age | ||||||
≤68 year vs. ≥69 year | 3.9 | (1.0–14.9) | 0.04 | 3.6 | (0.9–13.9) | 0.06 |
Sex | ||||||
Male vs. Female | 1.7 | (0.5–5.1) | 0.38 | - | - | - |
Smoking status | ||||||
Smoker vs. never smoker | 2.3 | (0.6–8.8) | 0.22 | - | - | - |
CT findings | ||||||
Pure-solid LAD * vs. part-solid LAD | 8.7 | (1.1–68.7) | 0.04 | 8.0 | (1.0–63.8) | 0.05 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Suda, K.; Shimoji, M.; Shimizu, S.; Sato, K.; Chiba, M.; Tomizawa, K.; Takemoto, T.; Soh, J.; Mitsudomi, T. Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. Biomolecules 2019, 9, 456. https://doi.org/10.3390/biom9090456
Suda K, Shimoji M, Shimizu S, Sato K, Chiba M, Tomizawa K, Takemoto T, Soh J, Mitsudomi T. Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. Biomolecules. 2019; 9(9):456. https://doi.org/10.3390/biom9090456
Chicago/Turabian StyleSuda, Kenichi, Masaki Shimoji, Shigeki Shimizu, Katsuaki Sato, Masato Chiba, Kenji Tomizawa, Toshiki Takemoto, Junichi Soh, and Tetsuya Mitsudomi. 2019. "Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas" Biomolecules 9, no. 9: 456. https://doi.org/10.3390/biom9090456